Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:307057rdf:typepubmed:Citationlld:pubmed
pubmed-article:307057lifeskim:mentionsumls-concept:C0205474lld:lifeskim
pubmed-article:307057lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:307057lifeskim:mentionsumls-concept:C0004927lld:lifeskim
pubmed-article:307057lifeskim:mentionsumls-concept:C0000544lld:lifeskim
pubmed-article:307057lifeskim:mentionsumls-concept:C1555903lld:lifeskim
pubmed-article:307057lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:307057lifeskim:mentionsumls-concept:C1515926lld:lifeskim
pubmed-article:307057pubmed:issue3lld:pubmed
pubmed-article:307057pubmed:dateCreated1978-8-28lld:pubmed
pubmed-article:307057pubmed:abstractTextIntracisternal administration of 5,7-dihydroxytryptamine (5,7-DHT) to immature rats produced a marked reduction of brain norepinephrine and serotonin. Accompanying these reductions of brain amines were a decrease in body weight and alterations in behavior. After treatment with 5,7-DHT at 3 days of age, locomotor activity was significantly elevated at 14 days of age, but was reduced at 28 days of age. 5,7-DHT alone also induced a significant deficit in acquisition of the shuttle-box avoidance response and blocked body movements observed after decapitation. Treatment with either pargyline or desipramine before injection of 5,7-DHT eliminated the effect of 5,7-DHT on noradrenergic fibers while enhancing the effects of 5,7-DHT on brain serotonergic fibers. These treatments also minimized the deficits of 5,7-DHT on growth and on acquisition of the avoidance response and reversed the blockade of decapitation convulsions. However, animals pretreated with pargyline or desipramine before they received 5,7-DHT still demonstrated hyperactivity at 14 days of age equivalent to that observed in neonates that received only 5,7-DHT. Furthermore, a behavioral syndrome induced by 30 mg/kg of 5-hydroxytryptamine was markedly potentiated by all of the 5,7-DHT treatments which suggest that serotonin receptors were supersensitive.lld:pubmed
pubmed-article:307057pubmed:languageenglld:pubmed
pubmed-article:307057pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:307057pubmed:citationSubsetIMlld:pubmed
pubmed-article:307057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:307057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:307057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:307057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:307057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:307057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:307057pubmed:statusMEDLINElld:pubmed
pubmed-article:307057pubmed:monthJunlld:pubmed
pubmed-article:307057pubmed:issn0022-3565lld:pubmed
pubmed-article:307057pubmed:authorpubmed-author:BreeseG RGRlld:pubmed
pubmed-article:307057pubmed:authorpubmed-author:MuellerR ARAlld:pubmed
pubmed-article:307057pubmed:authorpubmed-author:VogelR ARAlld:pubmed
pubmed-article:307057pubmed:issnTypePrintlld:pubmed
pubmed-article:307057pubmed:volume205lld:pubmed
pubmed-article:307057pubmed:ownerNLMlld:pubmed
pubmed-article:307057pubmed:authorsCompleteYlld:pubmed
pubmed-article:307057pubmed:pagination587-95lld:pubmed
pubmed-article:307057pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:307057pubmed:meshHeadingpubmed-meshheading:307057-A...lld:pubmed
pubmed-article:307057pubmed:meshHeadingpubmed-meshheading:307057-B...lld:pubmed
pubmed-article:307057pubmed:meshHeadingpubmed-meshheading:307057-R...lld:pubmed
pubmed-article:307057pubmed:meshHeadingpubmed-meshheading:307057-B...lld:pubmed
pubmed-article:307057pubmed:meshHeadingpubmed-meshheading:307057-F...lld:pubmed
pubmed-article:307057pubmed:meshHeadingpubmed-meshheading:307057-M...lld:pubmed
pubmed-article:307057pubmed:meshHeadingpubmed-meshheading:307057-A...lld:pubmed
pubmed-article:307057pubmed:meshHeadingpubmed-meshheading:307057-B...lld:pubmed
pubmed-article:307057pubmed:meshHeadingpubmed-meshheading:307057-A...lld:pubmed
pubmed-article:307057pubmed:meshHeadingpubmed-meshheading:307057-P...lld:pubmed
pubmed-article:307057pubmed:meshHeadingpubmed-meshheading:307057-5...lld:pubmed
pubmed-article:307057pubmed:meshHeadingpubmed-meshheading:307057-D...lld:pubmed
pubmed-article:307057pubmed:meshHeadingpubmed-meshheading:307057-B...lld:pubmed
pubmed-article:307057pubmed:meshHeadingpubmed-meshheading:307057-D...lld:pubmed
pubmed-article:307057pubmed:meshHeadingpubmed-meshheading:307057-5...lld:pubmed
pubmed-article:307057pubmed:meshHeadingpubmed-meshheading:307057-D...lld:pubmed
pubmed-article:307057pubmed:year1978lld:pubmed
pubmed-article:307057pubmed:articleTitleBiochemical and behavioral alterations in developing rats treated with 5,7-dihydroxytryptamine.lld:pubmed
pubmed-article:307057pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:307057pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:307057pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:307057lld:pubmed